Eloxx Pharmaceuticals, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2014 | FY2013 | FY2012 | FY2010 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $6.4M | $0 | $182.2K | $7.8K | $200.0K | $140.0K |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | — | — | — | $3.3M | $2.1M | $2.6M | $2.6M |
| SG&A Expense | $3.4M | $5.3M | $8.7M | $3.7M | $2.5M | $2.7M | $2.3M |
| Operating Income | $-6.4M | $-2.5M | $-17.3M | $-9.1M | $-4.7M | $-5.4M | $-4.8M |
| Operating Margin | — | -38.8% | — | -5,019.9% | -59,476.9% | -2,705.8% | -3,461.8% |
| Interest Expense | — | — | — | — | $47.5K | $0 | $586.5K |
| Pretax Income | $-6.0M | $-3.1M | $-17.1M | $-9.2M | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | — | — | — |
| Net Income | $-6.0M | $-3.1M | $-17.1M | $-9.2M | $-6.1M | $-5.1M | $-13.4M |
| Net Margin | — | -49.4% | — | -5,062.4% | -78,303.4% | -2,533.1% | -9,559.7% |
| EPS (Basic) | $-0.49 | $-0.84 | $-6.63 | $-0.84 | $-1.70 | $-2.60 | $-0.22 |
| EPS (Diluted) | $-0.49 | $-0.84 | $-6.63 | $-0.84 | $-1.70 | $-2.60 | $-0.22 |
| Shares Outstanding (Basic) | 12.3M | 3.8M | 2.6M | 41.5M | 695.7M | 350.3M | — |
| Shares Outstanding (Diluted) | 12.3M | 3.8M | 2.6M | 41.5M | 695.7M | 350.3M | — |
| Dividends Per Share | — | — | — | — | — | — | — |